Please login to the form below

Not currently logged in
Email:
Password:

Hollingsworth leaves cancer charity for ABPI

Andrew Hollingsworth appointed policy manager at pharma industry body

Andrew Hollingsworth is to leave the third sector to join industry, moving from Cancer Research UK to the Association of the British Pharmaceutical Industry (ABPI).

Hollingsworth will join the UK pharma trade body on November 25 as policy manager. He leaves his role as public affairs manager at Cancer Research UK.

He will use his experience in the third sector in his new role, which will see him lead the ABPI's work to engage with patient groups. This includes the Patient Organisation Forum, which aims to identify mutual interest and improve collaboration between industry and patient organisations.

Hollingsworth also has industry experience spending more than five years at Novartis a senior manager, public affairs. This followed a period in politics as parliamentary assistant in the European Parliament.

Commenting on his new role, Hollingsworth said: “I am keen to develop the ABPI's engagement with patient organisations in an open, transparent and constructive dialogue."

13th November 2013

From: Research, Sales, Marketing, Regulatory, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics